In ESMO 2026, 3SBio/ Pfizer updated the China Ph2 results for tivunatamig (707/ PF’4404) in 1L NSCLC in combination with chemo. 122 non-squamous (nsq) and 139 squamous (sq) patients were enrolled. In the 10mg/kg tivunatamig + chemo subgroup, nsq mPFS was 13.8 months vs. 9.7 months of tislelizumab + chemo. In sq-NSCLC, mPFS was 13.6 months with paclitaxel and 13.4 months with nab-paclitaxel vs. 8.3 months for tislelizumab group. In our view, the updated results should further support tivunatamig’s competitive profile and global development potential.